Catalent Inc Stock Forecast for 2023 - 2025 - 2030

Updated on 09/25/2023

Stock Rating
15
Price Target
$73.00
Consensus
Neutral
Upside
59.32%
Analysts
3
Stock Rating
15
Upside
59.32%
Analysts
3
Price Target
$73.00

Catalent Inc Stock Forecast and Price Target

The average price target of $73.00 for Catalent Inc's stock set by three distinguished analysts in recent weeks would represent a potential upside of approximately 59.32% from the last closing price in September, 2023 if reached by the end of the year. This potential increase is based on a high estimate of $100.00 and a low estimate of $58.00. Even if you are not interested in CTLT stock, it is still imperative to be aware of its competitors.

$73.00

59.32% Upside

Hold
Hold

Catalent Inc Fair Value Forecast for 2023 - 2025 - 2030

In the last four years, Catalent Inc has seen a decline in its Price, from $55.89 to $7.10 – a 87.29% decrease. In the next year, analysts believe that Fair Value will reach $83.99 – an increase of 1082.61%. For the next four years, the forecast is for Fair Value to grow by 1991.30%.

2027 Fair Value Forecast
$83.99
2028 Fair Value Forecast
$106.84
2029 Fair Value Forecast
$125.68
2030 Fair Value Forecast
$148.53
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
LLY Stock Forecast Eli Lilly & Co Outperform 14
$552.32 Buy/Sell $333.19 -27.58%
JNJ Stock Forecast Johnson & Johnson Outperform 10
$160.26 Buy/Sell $179.95 12.63%
PFE Stock Forecast Pfizer Inc Outperform 3
$32.98 Buy/Sell $44.13 59.64%
MRK Stock Forecast Merck Outperform 5
$105.84 Buy/Sell $99.57 11.49%
BMY Stock Forecast Bristol-Myers Squibb Co Outperform 2
$59.16 Buy/Sell $80.99 40.30%

Catalent Inc Revenue Forecast for 2023 - 2025 - 2030

Catalent Inc's Revenue has seen impressive growth In the last four years, rising from $2.52B to $4.83B – a growth of 91.74%. In the next year, analysts believe that Revenue will reach $5.17B – an increase of 7.09%. For the next four years, the forecast is for Revenue to grow by 34.22%.

2027 Rev Forecast
$5.17B
2028 Rev Forecast
$5.35B
2029 Rev Forecast
$5.87B
2030 Rev Forecast
$6.48B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
VRTX Stock Forecast Vertex Pharmaceuticals Inc Outperform 13
$350.67 Buy/Sell $384.26 -7.04%
ZTS Stock Forecast Zoetis Inc Outperform 18
$177.72 Buy/Sell $209.70 15.35%
REGN Stock Forecast Regeneron Pharmaceuticals Inc Outperform 2
$834.64 Buy/Sell $796.73 -6.31%

Catalent Inc Dividend per Share Forecast for 2023 - 2025 - 2030

Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
BAX Stock Forecast Baxter International Inc Outperform 17
$37.50 Buy/Sell $60.73 54.67%
ALNY Stock Forecast Alnylam Pharmaceuticals Inc Outperform 7
$170.77 Buy/Sell $244.18 46.98%
VTRS Stock Forecast Viatris Inc Hold 8
$9.71 Buy/Sell $13.70 39.03%

Catalent Inc Free Cash Flow Forecast for 2023 - 2025 - 2030

In the last four years, Catalent Inc's Free Cash Flow has seen an increase, rising from $30.00M to $364.00T. This represents a growth of 1213330946.67%. In the following year, 1 experts forecast Catalent Inc's Free Cash Flow will decrease by 100.00%, to $270.00M. In 2030, professionals predict that Catalent Inc's Free Cash Flow will decrease by 100.00%, to $699.00M.

2026 FCF Forecast
$0.27B
2027 FCF Forecast
$0.30B
2028 FCF Forecast
$0.43B
2029 FCF Forecast
$0.57B
2030 FCF Forecast
$0.70B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
UTHR Stock Forecast United Therapeutics Corp Outperform 12
$224.06 Buy/Sell $280.69 31.66%
IONS Stock Forecast Ionis Pharmaceuticals Inc Outperform 9
$42.67 Buy/Sell $52.42 17.18%
PRGO Stock Forecast Perrigo Co PLC Buy 16
$32.19 Buy/Sell $47.75 47.56%

Catalent Inc Net Income Forecast for 2023 - 2025 - 2030

In the last four years, Catalent Inc's Net Income has grown, moving from $137.00M to $519.00M – an increase of 278.83%. According to 1 prominent analysts, Catalent Inc's Net Income will fall by 19.85% in the next year, reaching $416.00M. Looking ahead to five years, experts forecast that Net Income will grow by 63.39%.

2026 NI Forecast
$0.42B
2027 NI Forecast
$0.49B
2028 NI Forecast
$0.62B
2029 NI Forecast
$0.72B
2030 NI Forecast
$0.85B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
BCPC Stock Forecast Balchem Outperform 18
$126.67 Buy/Sell $163.67 29.47%
NEOG Stock Forecast Neogen Hold 16
$19.48 Buy/Sell $37.00 30.90%
CYTK Stock Forecast Cytokinetics Inc Outperform 10
$30.00 Buy/Sell $62.67 100.00%

Catalent Inc EBITDA Forecast for 2023 - 2025 - 2030

Catalent Inc's EBITDA has seen growth In the last four years, going from $522.00M to $727.00M – a gain of 39.27% In the next year, analysts believe that EBITDA will reach $1.13B – an increase of 54.88%. For the next five years, the forecast is forEBITDA to grow by 150.89%.

2026 EBITDA Forecast
$1.13B
2027 EBITDA Forecast
$1.27B
2028 EBITDA Forecast
$1.43B
2029 EBITDA Forecast
$1.62B
2030 EBITDA Forecast
$1.82B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
TGTX Stock Forecast TG Therapeutics Outperform 9
$8.97 Buy/Sell $73.38 111.82%
INDV Stock Forecast Indivior PLC Buy 14
£21.51 Buy/Sell £3.79 -77.96%
PCRX Stock Forecast Pacira BioSciences Outperform 16
$32.82 Buy/Sell $79.67 137.66%

Catalent Inc EBIT Forecast for 2023 - 2025 - 2030

In the last three years, EBIT for Catalent Inc has grown by 157.68%, going from $293.00M to $755.00M. In the coming year, analysts are expecting an increase in EBIT, predicting it will reach $1.03B – an increase of 36.03%. Over the next five years, experts anticipate that EBIT growth for Catalent Inc will be 42.53%.

2026 EBIT Forecast
$1.03B
2027 EBIT Forecast
$1.15B
2028 EBIT Forecast
$1.29B
2029 EBIT Forecast
$1.09B
2030 EBIT Forecast
$1.08B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
CORT Stock Forecast Corcept Therapeutics Outperform 16
$32.32 Buy/Sell $0.00 -8.73%
AMPH Stock Forecast Amphastar Pharmaceuticals Outperform 14
$45.96 Buy/Sell $41.00 -4.26%
IRWD Stock Forecast Ironwood Pharmaceuticals Hold 14
$8.53 Buy/Sell $12.60 46.54%

Catalent Inc EPS Price Prediction Forecast for 2023 - 2025 - 2030

In the last four years, Catalent Inc has seen a decline in its EPS, from $1.81 to $0.23 – a 87.29% decrease. In the next year, analysts believe that EPS will reach $2.72 – an increase of 1082.61%. For the next four years, the forecast is for EPS to grow by 1991.30%.

2027 EPS Forecast
$2.72
2028 EPS Forecast
$3.46
2029 EPS Forecast
$4.07
2030 EPS Forecast
$4.81
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
SUPN Stock Forecast Supernus Pharmaceuticals Outperform 16
$30.06 Buy/Sell $35.50 13.11%
LGND Stock Forecast Ligand Pharmaceuticals Outperform 14
$58.86 Buy/Sell $195.43 169.28%
MDGL Stock Forecast Madrigal Pharmaceuticals Outperform 4
$150.96 Buy/Sell $170.08 15.92%